In the light of the settlement of the majority of glyphosate-related plaintiffs, Bayer took €12,050m legal costs into account (also for dicamba and PCB). Regarding future litigation, there is currently no agreement in place. Bayer’s operational performance was less pronounced in Q2, despite Crop Science’s stronger one. Pharmaceuticals and Consumer Health reported weaker than expected figures. Management now expects a stronger negative impact from the pandemic and has adjusted
04 Aug 2020
Nasty marks of reality
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Nasty marks of reality
Bayer AG (BAYN:WBO) | 0 0 0.5% | Mkt Cap: 80,975m
- Published:
04 Aug 2020 -
Author:
Martin Schnee -
Pages:
3
In the light of the settlement of the majority of glyphosate-related plaintiffs, Bayer took €12,050m legal costs into account (also for dicamba and PCB). Regarding future litigation, there is currently no agreement in place. Bayer’s operational performance was less pronounced in Q2, despite Crop Science’s stronger one. Pharmaceuticals and Consumer Health reported weaker than expected figures. Management now expects a stronger negative impact from the pandemic and has adjusted